The circular RNome of primary breast cancer

Marcel Smid, Saskia M. Wilting, Katharina Uhr, F. Germán Rodríguez-González, Vanja De Weerd, Wendy J.C. Prager-Van Der Smissen, Michelle Van Der Vlugt-Daane, Anne Van Galen, Serena Nik-Zainal, Adam Butler, Sancha Martin, Helen R. Davies, Johan Staaf, Marc J. Van De Vijver, Andrea Richardson, Gaëten MacGrogan, Roberto Salgado, Gert G.G.M. Van Den Eynden, Colin A. Purdie, Alastair M. ThompsonCarlos Caldas, Paul N. Span, Fred C.G.J. Sweep, Peter T. Simpson, Sunil R. Lakhani, Steven Van Laere, Christine Desmedt, Angelo Paradiso, Jorunn Eyfjord, Annegien Broeks, Anne Vincent-Salomon, Andrew P. Futreal, Stian Knappskog, Tari King, Alain Viari, Anne Lise Børresen-Dale, Hendrik G. Stunnenberg, Mike Stratton, John A. Foekens, Anieta M. Sieuwerts, John W.M. Martens

Research output: Contribution to journalArticle

Abstract

Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although their functional roles are debated. We analyzed RNA-seq data of 348 primary breast cancers and developed a method to identify circRNAs that does not rely on unmapped reads or known splice junctions. We identified 95,843 circRNAs, of which 20,441 were found recurrently. Of the circRNAs that match exon boundaries of the same gene, 668 showed a poor or even negative (R <0.2) correlation with the expression level of the linear gene. In silico analysis showed only a minority (8.5%) of circRNAs could be explained by known splicing events. Both these observations suggest that specific regulatory processes for circRNAs exist. We confirmed the presence of circRNAs of CNOT2, CREBBP, and RERE in an independent pool of primary breast cancers. We identified circRNA profiles associated with subgroups of breast cancers and with biological and clinical features, such as amount of tumor lymphocytic infiltrate and proliferation index. siRNA-mediated knockdown of circCNOT2 was shown to significantly reduce viability of the breast cancer cell lines MCF-7 and BT-474, further underlining the biological relevance of circRNAs. Furthermore, we found that circular, and not linear, CNOT2 levels are predictive for progression-free survival time to aromatase inhibitor (AI) therapy in advanced breast cancer patients, and found that circCNOT2 is detectable in cell-free RNA from plasma. We showed that circRNAs are abundantly present, show characteristics of being specifically regulated, are associated with clinical and biological properties, and thus are relevant in breast cancer.

Original languageEnglish (US)
Pages (from-to)356-366
Number of pages11
JournalGenome Research
Volume29
Issue number3
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Smid, M., Wilting, S. M., Uhr, K., Rodríguez-González, F. G., De Weerd, V., Prager-Van Der Smissen, W. J. C., Van Der Vlugt-Daane, M., Van Galen, A., Nik-Zainal, S., Butler, A., Martin, S., Davies, H. R., Staaf, J., Van De Vijver, M. J., Richardson, A., MacGrogan, G., Salgado, R., Van Den Eynden, G. G. G. M., Purdie, C. A., ... Martens, J. W. M. (2019). The circular RNome of primary breast cancer. Genome Research, 29(3), 356-366. https://doi.org/10.1101/gr.238121.118